NasdaqGS:NTRABiotechs
Assessing Natera (NTRA) Valuation After Patent Win Product Momentum And Upcoming Cancer Data
Interest in Natera (NTRA) has picked up after several company specific catalysts, including a favorable patent ruling with ongoing royalties, strong uptake of its Signatera test, and fresh data coming to a leading cancer research meeting.
See our latest analysis for Natera.
Despite the recent catalysts, Natera’s share price has pulled back, with a 1 day share price return decline of 4.91% and a 90 day share price return decline of 17.62%, while the 1 year total shareholder return of 30.39%...